LGVN News and Press, Longeveron Inc. From 11/15/23

2023-11-15 17:02:17 ET Longeveron ( NASDAQ: LGVN ) files to sell 5.02M shares of class A common stock for holders. This preliminary prospectus is not an offer to sell. SEC Filing For further details see: Longeveron files to sell 5.02M shares of class A c...

Longeveron (NASDAQ: LGVN) , a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was featured in the latest episode of the Bell2Bell Podcast , a part of IBN’s sustained effort to provide specialized content distr...

LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sus...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is reporting on data from a long-term st...

Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-B TM As Adjunct to Stage II Surgery in HLHS - Enrollment ongoing in Phase 2 ELPIS II trial - MIAMI, Nov. 11, 2023 (GLOBE NEWSWIRE...

2023-11-10 10:27:08 ET Longeveron Inc. (LGVN) Q3 2023 Earnings Conference Call November 10, 2023 08:30 A.M. ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors, LLC Wa’el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO ...

2023-11-10 07:33:29 ET More on Longeveron Longeveron: Alzheimer's Phase 2 Data Around The Corner Longeveron to implement ~$4M registered direct offering of shares Longeveron falls after mid-stage data for Alzheimer’s candidate For further details see: ...

Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions ...

Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...

Longeveron Inc. (LGVN) is expected to report $-0.24 for Q3 2023